Quantcast

Latest Clinical endpoint Stories

2014-03-18 23:26:23

Launch of ADDPLAN® 6.1 to Expedite and Improve Decision-Making in Clinical Trials Reston, Virginia (PRWEB) March 18, 2014 Aptiv Solutions, a global biopharmaceutical and medical device development services company leading the design and implementation of innovative approaches that improve data quality, efficiency, and productivity of product development, today announced the release of ADDPLAN® 6.1, the first statistical software to enable the use of surrogate endpoints to...

2014-02-25 23:26:44

Streamlined process will improve efficiency and quality of data collection Reston, Virginia (PRWEB) February 25, 2014 Aptiv Solutions, a global biopharmaceutical and medical device development services company leading the design and implementation of innovative approaches that improve data quality, efficiency and productivity of product development, today announced the launch of a new, streamlined process to support endpoint adjudication for drug and medical device companies. Regulatory...

2014-01-13 08:30:13

Topline Data Will Be Presented at Biotech Showcase HEIDELBERG, Germany, Jan. 13, 2014 /PRNewswire/ -- Apogenix, a clinical stage biopharmaceutical company, announced today the successful completion of its phase II proof-of-concept trial with APG101 in patients with recurrent glioblastoma. All endpoints of the randomized controlled trial that compared the efficacy and safety of a combination therapy of APG101 and radiotherapy versus radiotherapy alone were achieved or...

2014-01-09 16:25:42

Highlights Include ICT-107 Results to Date, Ongoing Data Analyses and Phase III Planning LOS ANGELES, Jan. 9, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today issued the following letter to shareholders providing an update on the Company's ICT-107 clinical program in patients with newly diagnosed glioblastoma (GBM). (Logo: http://photos.prnewswire.com/prnh/20140109/AQ43875LOGO) To Our Shareholders: Since the December 11, 2013 announcement of...

2013-01-10 14:03:20

Spin and bias exist in a high proportion of published studies of the outcomes and adverse side-effects of phase III clinical trials of breast cancer treatments, according to new research published in the cancer journal Annals of Oncology today (Thursday). In the first study to investigate how accurately outcomes and side-effects are reported in breast cancer trials, researchers at the Princess Margaret Cancer Centre and University of Toronto (Toronto, Canada) found that in a third of all...

2011-07-27 13:30:00

COLORADO SPRINGS, Colo., July 27, 2011 /PRNewswire/ -- Stryker Neurovascular, a division of Stryker Corporation, today announced the results of its Matrix and Platinum Science (MAPS) Trial during the Society of NeuroInterventional Surgery (SNIS) 8th Annual Meeting in Colorado Springs. The MAPS Trial establishes a new standard for the measurement of aneurysm treatment success, target aneurysm recurrence rate (TAR)*, and proves that coiling is an excellent treatment for both ruptured and...

2011-03-28 09:13:00

BALA CYNWYD, Pa., March 28, 2011 /PRNewswire/ -- Applied Clinical Intelligence, LLC (ACI), an industry leader in clinical endpoint adjudication committees and independent data monitoring committees (www.icommittees.com), announces the opening of registration for a complimentary breakfast seminar in Cambridge, MA. The 90-minute seminar will focus on aligning independent expert committees with development goals. This is a unique opportunity to learn practical advice about effective design...

2010-10-19 08:40:00

SAN FRANCISCO, Oct. 19 /PRNewswire/ -- endpoint Clinical (www.endpointclinical.com), a leader in Integrated Response Technology (IRT) development, today announced the release of PULSE 2.0(TM). endpoint PULSE is a proprietary platform that enables the configuration of fully validated, custom IRT systems for clinical trials in a fraction of the time required by traditional development. New in PULSE 2.0 is the ability for project managers to create and manage client-specific templates,...

2010-01-05 07:30:00

NATICK, Mass., Jan. 5 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced that it has completed enrollment in its MAPS(TM) clinical trial, which is studying the coiling of intracranial aneurysms. This prospective, randomized trial commenced enrollment in 2007 and has reached its goal of 630 patients, enrolled at 47 hospitals in 11 countries. Principal investigators for the trial are Anil Gholkar, O.B.E., M.B.B.S., Clay Johnston, M.D., Ph.D., and Cameron...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related